FY2026 EPS Estimate for Krystal Biotech Increased by Analyst

Krystal Biotech, Inc. (NASDAQ:KRYS) – Equities researchers at HC Wainwright increased their FY2026 earnings per share estimates for shares of Krystal Biotech in a research note issued to investors on Monday, November 2nd. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of $7.71 for the year, up from their prior estimate of $7.10. HC Wainwright currently has a “Buy” rating and a $361.00 price objective on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $7.33 per share. HC Wainwright also issued estimates for Krystal Biotech’s Q4 2026 earnings at $2.04 EPS, FY2027 earnings at $7.50 EPS and FY2028 earnings at $12.82 EPS.

A number of other research analysts have also recently issued reports on KRYS. Jefferies Financial Group reiterated a “buy” rating and issued a $474.00 target price on shares of Krystal Biotech in a research report on Monday, July 13th. Chardan Capital raised shares of Krystal Biotech to a “strong-buy” rating in a report on Monday, August 3rd. TD Cowen decreased their price target on shares of Krystal Biotech from $403.00 to $380.00 and set a “buy” rating on the stock in a report on Tuesday. Zacks Research cut shares of Krystal Biotech from a “hold” rating to a “strong sell” rating in a research report on Friday, October 23rd. Finally, William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research note on Wednesday, September 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Krystal Biotech currently has an average rating of “Moderate Buy” and a consensus price target of $375.00.

Krystal Biotech Stock Up 3.1%

Shares of KRYS stock opened at $305.03 on Wednesday. The business has a fifty day simple moving average of $335.72 and a 200 day simple moving average of $308.77. The company has a market cap of $9.03 billion, a P/E ratio of 41.39 and a beta of 0.56. Krystal Biotech has a twelve month low of $192.52 and a twelve month high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, November 2nd. The company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.26. Krystal Biotech had a return on equity of 17.02% and a net margin of 47.91%. The company had revenue of $127.34 million for the quarter, compared to analyst estimates of $125.77 million.

Hedge Funds Weigh In On Krystal Biotech

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Heritage Family Offices LLP acquired a new position in shares of Krystal Biotech during the third quarter worth $25,000. Silvant Capital Management LLC acquired a new stake in Krystal Biotech in the second quarter valued at $30,000. Western Wealth Management LLC acquired a new stake in Krystal Biotech in the first quarter valued at $34,000. USA Financial Formulas acquired a new stake in Krystal Biotech in the first quarter valued at $44,000. Finally, Integrated Wealth Concepts LLC bought a new position in Krystal Biotech during the 2nd quarter worth $46,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Krystal Biotech

In other news, Director Dino A. Rossi sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the transaction, the director owned 50,000 shares of the company’s stock, valued at $16,456,000. This represents a 33.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the completion of the transaction, the insider owned 1,302,145 shares of the company’s stock, valued at approximately $467,886,741.40. This trade represents a 1.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 13.10% of the company’s stock.

Key Krystal Biotech News

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Third-quarter revenue rose about 30% to $127.34 million, and EPS of $2.05 topped analyst expectations. Vyjuvek’s performance helped drive the growth. Krystal Biotech Q3 Net Income Falls, Revenue Rises; Shares Up Pre-Bell
• Positive Sentiment: The company announced a $400 million share-repurchase program, which may support demand for the stock. Krystal outlines $400M share repurchase
• Neutral Sentiment: Citigroup, TD Cowen, and RBC trimmed their price targets but retained Buy or Outperform ratings, signaling continued optimism alongside more cautious valuation assumptions. RBC on Krystal Biotech prospects
• Negative Sentiment: Net income declined from a year earlier, and several pipeline timelines have slipped into 2027. Those factors appear to have weighed on shares despite the earnings beat and revenue growth. Krystal beats on Vyjuvek strength, but pipeline timelines slip

Krystal Biotech Company Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company’s platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal’s lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.